EG18335A - Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis - Google Patents
Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosisInfo
- Publication number
- EG18335A EG18335A EG53/88A EG5388A EG18335A EG 18335 A EG18335 A EG 18335A EG 53/88 A EG53/88 A EG 53/88A EG 5388 A EG5388 A EG 5388A EG 18335 A EG18335 A EG 18335A
- Authority
- EG
- Egypt
- Prior art keywords
- hyperlipidaemia
- treatment
- pyridoxine
- antherosclerosis
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Pyridoxine derivatives and their salts, in particular pyridoxal, pyridoxal phosphate, pyridoxamine and pyridoxamine phosphate, are used in the prophylaxis and treatment of hyperlipidaemia and atherosclerosis. Exceptions are pyridoxine-5'-phosphoric acid glutamate and aspartate, which are described in DE 2,461,742 C2. Natural, highly compatible, chemically unambiguously described and adequately stable substances having good activity for long term treatments are thereby made available. The buccal administration form and enteric-resistant forms have proved particularly suitable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19873705549 DE3705549A1 (en) | 1987-02-18 | 1987-02-18 | USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS |
Publications (1)
Publication Number | Publication Date |
---|---|
EG18335A true EG18335A (en) | 1992-09-30 |
Family
ID=6321453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EG53/88A EG18335A (en) | 1987-02-18 | 1988-02-01 | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0282696B1 (en) |
JP (2) | JPH0710777B2 (en) |
KR (1) | KR950009094B1 (en) |
AT (1) | ATE82125T1 (en) |
CA (1) | CA1340246C (en) |
DE (2) | DE3705549A1 (en) |
DK (1) | DK55888A (en) |
EG (1) | EG18335A (en) |
ES (1) | ES2052609T3 (en) |
GR (1) | GR3006693T3 (en) |
HU (1) | HUT47850A (en) |
ZA (1) | ZA88577B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6740668B1 (en) | 1995-08-28 | 2004-05-25 | Kansas University Medical Center | Methods for inhibiting diabetic complications |
US6716858B1 (en) | 1995-08-28 | 2004-04-06 | Kansas University Medical Center | Methods for inhibiting diabetic complications |
US6228858B1 (en) | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US6730686B1 (en) | 1995-09-12 | 2004-05-04 | Kansas University Medical Center | Methods for inhibiting oxidative modification of proteins |
US6750209B1 (en) | 1995-09-12 | 2004-06-15 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5744451A (en) | 1995-09-12 | 1998-04-28 | Warner-Lambert Company | N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity |
US7030146B2 (en) | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
AU1444600A (en) * | 1998-10-09 | 2000-05-01 | Kansas University Medical Center | Methods for inhibiting oxidative modification of proteins |
ATE306489T1 (en) | 1999-03-08 | 2005-10-15 | Medicure Inc | PYRIDOXAL ANALOGUE FOR THE TREATMENT OF DISORDERS CAUSED BY VITAMIN B6 DEFICIENCY |
AU5840200A (en) | 1999-07-13 | 2001-01-30 | Medicure Inc. | Treatment of diabetes and related pathologies |
WO2001013900A2 (en) | 1999-08-24 | 2001-03-01 | Medicure International Inc. | Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds |
DE60110054T2 (en) | 2000-02-29 | 2006-03-09 | Medicure International Inc. | CARDIOPROTECTIVE PHOSPHONATES |
US6586414B2 (en) | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6548519B1 (en) | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
NZ523815A (en) | 2000-07-07 | 2004-07-30 | Medicure Int Inc | Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
US6897228B2 (en) | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
AU2004224562A1 (en) * | 2003-03-27 | 2004-10-07 | Medicure Inc. | Modulation of cell death |
WO2006050598A1 (en) | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US7375112B2 (en) * | 2005-01-05 | 2008-05-20 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
FR3038227B1 (en) | 2015-06-30 | 2018-08-17 | Assistance Publique - Hopitaux De Paris | EFFERVESCENT FORMULATION BASED ON PYRIDOXAL-5-PHOSPHATE |
JP7244024B2 (en) * | 2018-06-25 | 2023-03-22 | 学校法人近畿大学 | Collagen degradation inhibitor for blood vessel walls affected by nicotine intake |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3373E (en) | 1904-02-26 | 1904-10-27 | Joseph Louis Felix Garrigou | Process for treating emptying and organic waste, and overall apparatus for its implementation |
FR6707M (en) * | 1966-04-29 | 1969-02-17 | ||
GB1070120A (en) * | 1966-05-06 | 1967-05-24 | Tanabe Seiyaku Co | Pyridoxine derivative and the preparation thereof |
FR7238M (en) * | 1968-03-27 | 1969-09-01 | ||
FR2035765A1 (en) | 1969-03-06 | 1970-12-24 | Inst Rech Scient | Medicaments contg pyridoxine heparinates or - other vitamin b6 heparinates |
JPS5347110B2 (en) * | 1971-11-02 | 1978-12-19 | ||
FR2176509A2 (en) | 1972-03-21 | 1973-11-02 | Inst Rech Scient | Pyridoxine p-chlorophenoxyisobutyrate prodn - giving very pure product from corresp acid and pyridoxine |
JPS5018470A (en) * | 1973-05-31 | 1975-02-26 | ||
FR2260330A1 (en) | 1974-02-07 | 1975-09-05 | Innothera Lab Sa | Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index |
CH607773A5 (en) | 1974-12-24 | 1978-10-31 | Steigerwald Arzneimittelwerk | Process for the preparation of novel pyridoxine derivatives |
DE2461742C2 (en) | 1974-12-28 | 1983-01-27 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt | Pyridoxine-5'-phosphoric acid ester derivatives and their preparation and pharmaceuticals containing these compounds |
FR2349330A1 (en) * | 1976-04-29 | 1977-11-25 | Savini Emile | Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia |
JPS5347110A (en) * | 1976-10-12 | 1978-04-27 | Osaka Bosui Kensetsusha Kk | Impermeable wall forming method |
-
1987
- 1987-02-18 DE DE19873705549 patent/DE3705549A1/en not_active Withdrawn
-
1988
- 1988-01-20 AT AT88100747T patent/ATE82125T1/en not_active IP Right Cessation
- 1988-01-20 EP EP88100747A patent/EP0282696B1/en not_active Expired - Lifetime
- 1988-01-20 ES ES88100747T patent/ES2052609T3/en not_active Expired - Lifetime
- 1988-01-20 DE DE8888100747T patent/DE3875760D1/en not_active Expired - Fee Related
- 1988-01-28 ZA ZA880577A patent/ZA88577B/en unknown
- 1988-02-01 EG EG53/88A patent/EG18335A/en active
- 1988-02-03 DK DK055888A patent/DK55888A/en not_active Application Discontinuation
- 1988-02-16 HU HU88723A patent/HUT47850A/en unknown
- 1988-02-17 KR KR1019880001692A patent/KR950009094B1/en not_active IP Right Cessation
- 1988-02-17 JP JP63032943A patent/JPH0710777B2/en not_active Expired - Lifetime
- 1988-02-18 CA CA000559285A patent/CA1340246C/en not_active Expired - Fee Related
-
1992
- 1992-12-28 GR GR920403159T patent/GR3006693T3/el unknown
-
1994
- 1994-09-02 JP JP6209830A patent/JP2588686B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE82125T1 (en) | 1992-11-15 |
JPH07238020A (en) | 1995-09-12 |
DK55888A (en) | 1988-08-19 |
KR950009094B1 (en) | 1995-08-14 |
GR3006693T3 (en) | 1993-06-30 |
JPH0710777B2 (en) | 1995-02-08 |
EP0282696A3 (en) | 1989-06-14 |
EP0282696A2 (en) | 1988-09-21 |
KR880009649A (en) | 1988-10-04 |
JPS63203621A (en) | 1988-08-23 |
DE3705549A1 (en) | 1988-09-01 |
ZA88577B (en) | 1988-07-28 |
CA1340246C (en) | 1998-12-15 |
ES2052609T3 (en) | 1994-07-16 |
DK55888D0 (en) | 1988-02-03 |
HUT47850A (en) | 1989-04-28 |
DE3875760D1 (en) | 1992-12-17 |
EP0282696B1 (en) | 1992-11-11 |
JP2588686B2 (en) | 1997-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG18335A (en) | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis | |
KR950009098B1 (en) | Pharmaceutical composition for use in treating clot formation | |
AU2490297A (en) | Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis | |
HU896498D0 (en) | Process for preparation of low volatility salts | |
AU7316591A (en) | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders | |
DE69230526D1 (en) | POLYAMINIC ACID DISPERSING AGENT | |
DE3273611D1 (en) | Infusion solutions for heart therapy | |
AU2005188A (en) | Pharmaceutical composition for intranasal administration comprising gh-releasing hormone, a cholinergic agonist and in case a bile salt | |
HUT45564A (en) | Process for producing hirudine variants | |
GR900300043T1 (en) | Use of the enzyme-cofactor nadph in the preparation of a pharmaceutical, pharmaceutical and preparation thereof | |
PL306371A1 (en) | Diamine salts of clavulanic acid | |
MY103210A (en) | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds. | |
AU639097B2 (en) | Medicament for treating hyperlipidaemia and/or atherosclerosis | |
AU1463888A (en) | Nitrification-inhibiting agent | |
EP0355612A3 (en) | New furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
IL81549A0 (en) | Pharmaceutical compositions containing glycerophosphoryl-o-serine or a salt thereof,certain such novel salts and their preparation | |
AU589148B2 (en) | Medicament for the treatment of acquired immune deficiency syndrome and corresponding pharmaceutical compositions and method of treatment | |
EP0286802A3 (en) | Use of ofloxacin in treating or preventing locally periodontal disease | |
HU9200025D0 (en) | Medical preparations for treating depression | |
ZA871140B (en) | Synergistic chemical compositions for treating salmonellosis | |
GB8810322D0 (en) | Fine filler for dental purposes | |
DE3869772D1 (en) | ||
GR3015225T3 (en) | Pesticide composition. | |
IT1174592B (en) | Compsn. for treatment of diarrhoea | |
HU9201483D0 (en) | Process for the production of 1h-rh-analogues'acid additive salts, and for the production of medical preparations containing them |